Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;44(2):197-204.
doi: 10.1016/j.iac.2023.12.007. Epub 2024 Jan 12.

Endoscopic Features of Eosinophilic Esophagitis

Alain M Schoepfer  1 , Ekaterina Safroneeva  2 , Kathryn Peterson  3
Affiliations
Review

Endoscopic Features of Eosinophilic Esophagitis

Alain M Schoepfer et al. Immunol Allergy Clin North Am. 2024 May.

Abstract

Edema, rings, exudates, furrows, and strictures (EREFS) represent the major endoscopic features of eosinophilic esophagitis (EoE). The Endoscopic Reference System (EREFS) grading system is easy to learn and apply during daily clinical practice in the diagnosis and follow-up of EoE patients. When endoscopy is performed by an EoE-experienced physician, the EREFS criteria will identify the majority of EoE patients. The EREFS score from the area of greatest involvement of the esophagus should be reported. The EREFS grading system was formally validated as an endoscopy score and several randomized placebo-controlled trials have shown responsiveness of the EREFS score to therapeutic interventions.

Keywords: Edema; Eosinophilic esophagitis; Exudates; Furrows; Rings; Strictures.

PubMed Disclaimer

Conflict of interest statement

Disclosure A.M. Schoepfer received consulting fees and/or speaker fees and/or research grants from Avir Pharma, Inc., Adare/Ellodi Pharmaceuticals, Inc., AstraZeneca, AG, Switzerland, Receptos-Celgene-BMS Corp., Dr Falk Pharma, GmbH, Germany, Glaxo Smith Kline, AG, Nestlé S. A., Switzerland, Novartis, AG, Switzerland, and Regeneron-Sanofi Pharmaceuticals, Inc. E. Safroneeva reports (i) consulting fees from Avir Pharma, Inc., Aptalis Pharma, Inc., Celgene Corp., Novartis, AG, and Regeneron Pharmaceuticals Inc; (ii) being an employee of Tillotts Pharma AG. K. Peterson received (i) consulting fees and/or speaker fees from AGA, Alladapt, AstraZeneca, Allakos, Bristol Meyers Squibb, Ellodi, ITA group, Lecture LInx, Lucid, Nexstone (Ubiquity), WebMD, Peerview, PLatform Q health, Regeneron, Revolo, Sanofi, Takeda, WebMD; (ii) research support from AstraZeneca, Allakos, Regeneron-Sanofi, Revolo, Adare, Ellodi, Bristol Meyers Squibb, Celldex; and (iii) equity from Nexeos Bio.

References

Publication types

MeSH terms